$5.15
Today
as of Jul 22, 16:45 ET
Last 30 days
Recent Press Releases & News
Aligos Therapeutics Completes Enrollment in Phase 2 Study of Potential Chronic Hepatitis B Treatment
Aligos Therapeutics Announces the Completion of Enrollment in the Phase 2 B-SUPREME Study of Pevifoscorvir Sodium Under Development for the Treatment of Chronic HBV Infection
ALGS Stock Rallies 16% After-Hours On $25M Cash Boost From China Hepatitis B Drug Deal
Overview
52-week range
$4.82
$14
4% of range
Avg surprise (last 3)
+21.0%
Avg reaction (last 2)
-7.3%
0% positive
Earnings trends
EPS — actual vs estimate
Actual Estimate
Revenue vs Net Income
Revenue Net income
Earnings history
| Date | Period | Actual EPS | Est | Surprise | YoY %Δ | Day react | Source |
|---|---|---|---|---|---|---|---|
| Thu May 7, 2026 | Mar/2026 | $-2.21 | $-2.29 | +3.5% | -4.7% | -5.3% | earnings |
| Tue Sep 30, 2025 | Sep 2025 | $-3.04 | — | — | — | — | financials |
| Wed Aug 6, 2025 | Jun/2025 | $-1.53 | $-2.35 | +34.9% | — | — | earnings |
| Tue May 6, 2025 | Mar/2025 | $-2.11 | $-2.80 | +24.6% | — | -9.3% | earnings |
| Mon Sep 30, 2024 | Sep 2024 | $-3.07 | — | — | — | — | financials |
| Sun Jun 30, 2024 | Jun 2024 | $0.81 | — | — | — | — | financials |
| Sun Mar 31, 2024 | Mar 2024 | $-5.58 | — | — | — | — | financials |
| Sat Sep 30, 2023 | Sep 2023 | $-10.37 | — | — | — | — | financials |
| Fri Jun 30, 2023 | Jun 2023 | $-0.43 | — | — | — | — | financials |
Upcoming
| Date | Fiscal | Time | EPS Est | LY EPS | YoY %Δ |
|---|---|---|---|---|---|
| Wed Aug 5, 2026 | Jun/2026 | OTHER | -$1.40 | -$1.53 | +8.5% |
Financials
Income statement (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $3M | — | $741,000 | $965,000 | $311,000 | — | $1M | $1M |
| Cost of revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | $-27M | — | $-28M | $-19M | $-19M | — | $-20M | $-26M |
| Net income | $-23M | — | $-32M | $-16M | $43M | — | $-19M | $5M |
| EPS (diluted) | $-2.21 | — | $-3.04 | $-1.53 | $-2.11 | — | $-3.07 | $0.81 |
Balance sheet (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $30M | $18M | $42M | $19M | $74M | $37M | $35M | $45M |
| Inventory | — | — | — | — | — | — | — | — |
| Total current assets | $60M | $83M | $103M | $128M | $143M | $62M | $80M | $100M |
| Total assets | $65M | $89M | $110M | $135M | $151M | $70M | $88M | $109M |
| Long-term debt | — | — | — | — | — | — | — | — |
| Total liabilities | $33M | $35M | $38M | $33M | $34M | $99M | $38M | $42M |
| Total equity | $32M | $54M | $72M | $102M | $116M | $-29M | $50M | $67M |
Implied volatility — last 90 days
No IV snapshots yet for ALGS.
IV is captured twice daily (9:15 AM & 4:30 PM ET) for tickers with upcoming earnings. Comes online automatically once the next options refresh runs.